Abstract
In contrast to traditional aims in the treatment of Crohn’s disease, recent studies have identified mucosal healing as an important therapeutic goal. Conventional management focused predominantly on achieving clinical remission, without necessarily accomplishing response at a mucosal level. However, evidence has emerged demonstrating that achieving and maintaining mucosal healing can alter the natural history of the disease. Until recently this outcome seemed out of reach for treatment strategies designed only to ameliorate symptoms. This revelation gains pivotal importance when considered in conjunction with the advent of biological agents with the ability to effectively deliver this goal. In this chapter we will present the evidence, which gave rise to this critical change of paradigm. Despite this clear progress, there remain a number of unresolved issues regarding its implications for the monitoring and treatment of patients with Crohn’s disease. For instance, a universally accepted definition for mucosal healing has yet to be agreed. The same is true of the minimal clinically relevant change in endoscopic appearance. There are also practical issues regarding the integration of endoscopic goals into clinical treatment strategies. In this chapter we explore these issues in light of the latest evidence. The endoscopic indices used to objectively quantify disease activity in Crohn’s disease will also be described, along with their development, properties and practical use. Finally, we will make suggestions on how this understanding can be integrated into clinical practice to optimize the management of patients with Crohn’s disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56(4):453–5. PubMed PMID: 17369375, Pubmed Central PMCID: 1856849.
Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135(5):1442–7. PubMed PMID: 18848556.
Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996;110(1):45–51. PubMed PMID: 8536887.
Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100(8):1780–7. PubMed PMID: 16086715.
Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98(4):811–8. PubMed PMID: 2179031.
D’Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology. 1999;116(5):1029–34. PubMed PMID: 10220494.
van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109(1):129–35. PubMed PMID: 7797011.
Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412–22. PubMed PMID: 17681162.
Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24(7):762–9. PubMed PMID: 22517240.
Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983–9. PubMed PMID: 2668130, Pubmed Central PMCID: 1434265.
Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1992;102(5):1647–53. PubMed PMID: 1568574.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. PubMed PMID: 12047962.
Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102–11 e2. PubMed PMID: 22326435.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. PubMed PMID: 20393175.
Hebuterne X, Lemann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut. 2013;62(2):201–8. PubMed PMID: 22525883, Pubmed Central PMCID: 3551215.
Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7(1):15–29. PubMed PMID: 19949430.
Feagan BG, Sandborn WJ, D’Haens G, Pola S, McDonald JW, Rutgeerts P, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013;145(1):149–57 e2. PubMed PMID: 23528626.
Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006;63(4):558–65. PubMed PMID: 16564852.
Kim B, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. Am J Gastroenterol. 1999;94(11):3258–62. PubMed PMID: 10566726.
Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc. 1995;42(3):232–7. PubMed PMID: 7498688.
Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn’s disease: monitoring disease activity. Aliment Pharmacol Ther. 2003;17(2):11–7. PubMed PMID: 12786607.
Chutkan RK, Wayne JD. Endoscopy in inflammatory bowel disease. In: Kirshner JB, editor. Inflammatory bowel disease. 5th ed. Baltimore: Williams & Wilkins; 2000. p. 453–77.
Chutkan RK, Scherl E, Waye JD. Colonoscopy in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002;12(3):463–83, viii. PubMed PMID: 12486939.
Pera A, Bellando P, Caldera D, Ponti V, Astegiano M, Barletti C, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology. 1987;92(1):181–5. PubMed PMID: 3781186.
Khanna R, D’Haens D, Rutgeerts P, McDonald J, Daperno M, Feagan B, et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. CCFA2013.
Mary JY, Lemann M, Colombel JF, Lerebours E, Soule JC, Gendre JP, et al. Endoscopic remission and response in Crohn’s disease: an objective definition using the CDEIS. Gut. 2005;54(7).
Laharie D, Reffet A, Belleannee G, Chabrun E, Subtil C, Razaire S, et al. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther. 2011;33(6):714–21. PubMed PMID: 21235604.
Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn’s disease. Curr Med Res Opin. [Internet]. 2005;21(11):1741–54. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/129/CN-00553129/frame.html
Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, et al. Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013;145(5):978–86 e5. PubMed PMID: 23954314.
van der Woude CJ, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, et al. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn’s disease. Inflamm Bowel Dis. 2010;16(10):1708–16. PubMed PMID: 20848453.
Ferrante M, Noman M, Vermeire S, Van Assche G, Rutgeerts PJ. EoeasuptiCsdG. Evolution of endoscopic activity scores under placebo therapy in Crohn’s disease. Gastroenterology. 2010;138(5) S–358, http://www.gastrojournal.org/issue/S0016-5085(10)X6001-2.
Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest endosc. 2006;63(3):433–42; quiz 64. PubMed PMID: 16500392.
Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35(2):231–5. PubMed PMID: 7508411, Pubmed Central PMCID: 1374499.
Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–12. PubMed PMID: 15472670.
De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2013;19(2):429–44. PubMed PMID: 22539420.
Sipponen T, Nuutinen H, Turunen U, Farkkila M. Endoscopic evaluation of Crohn’s disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 2010;16(12):2131–6. PubMed PMID: 20848462.
Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162–9. PubMed PMID: 19755969.
af Bjorkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Farkkila M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47(5):528–37. PubMed PMID: 22356594.
Moskovitz DN, Daperno M, Van Assche G. Defining and validating cut-offs for the Simple Endocopic Score for Crohn’s Disease. Gastroenterology. 2007;132:S1097.
Reinisch W, Rutgeerts P, Panaccione R, D’Haens G, Thakkar R, Yu A, et al. Prediction of long-term clinical remission for adalimumab-treated patients with Crohn’s disease by identification of appropriate dichotomizing points for SES-CD. Gastroenterology. 2010;1385 (Suppl 1):S-8.
Archavlis E, Papamichael K, Tzivras D, Theodoropoulos I, Smyrnidis A, Konstantopoulos P, et al. Adalimumab for patients with Crohn’s disease and secondary loss of response or severe allergy to infliximab. J Crohns Colitis. 2011;5(1):S86.
Van Assche G, Magdelaine-Beuzelin C, D’Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134(7):1861–8. PubMed PMID: 18440315.
Hawkey C, Allez M, Ardizzone S, Clark M, Clark L, Colombel JF, et al. Clinical and endocopic improvement following hemopoietic stem cell transplantation in the ASTIC trial. J Crohns Colitis. 2013;7:S4.
Sandborn W, Panaccione R, Colombel JF, Louis E, Yang M, Thakkar R, et al. Development of three practical indices for mucosal healing among patients with moderate to severe Crohn’s disease. J Crohns Colitis. 2012;6:S3.
Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25(6):665–72. PubMed PMID: 6735250, Pubmed Central PMCID: 1432363.
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–63. PubMed PMID: 2394349.
Sands BE, Ooi CJ. A survey of methodological variation in the Crohn’s disease activity index. Inflamm Bowel Dis. 2005;11(2):133–8. PubMed PMID: 15677906.
Olaison G, Smedh K, Sjodahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992;33(3):331–5. PubMed PMID: 1568651, Pubmed Central PMCID: 1373822.
Katz JA. Postoperative endoscopic surveillance in Crohn’s disease: bottom up or top down? Gastrointest Endosc. 2007;66(3):541–3. PubMed PMID: 17725943.
Blum E, Katz JA. Postoperative therapy for Crohn’s disease. Inflamm Bowel Dis. 2009;15(3):463–72. PubMed PMID: 18942739.
Ferrante M, de Hertogh G, Hlavaty T, D’Haens G, Penninckx F, D'Hoore A, et al. The value of myenteric plexitis to predict early postoperative Crohn’s disease recurrence. Gastroenterology. 2006;130(6):1595–606. PubMed PMID: 16697723.
Biancone L, Cretella M, Tosti C, Palmieri G, Petruzziello C, Geremia A, et al. Local injection of infliximab in the postoperative recurrence of Crohn’s disease. Gastrointest Endosc. 2006;63(3):486–92. PubMed PMID: 16500402.
Aguas M, Bastida G, Cerrillo E, Beltran B, Iborra M, Sanchez-Montes C, et al. Adalimumab in prevention of postoperative recurrence of Crohn’s disease in high-risk patients. World J Gastroenterol. 2012;18(32):4391–8. PubMed PMID: 22969204, Pubmed Central PMCID: 3436056.
Biancone L, Calabrese E, Petruzziello C, Onali S, Caruso A, Palmieri G, et al. Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn’s disease. Inflamm Bowel Dis. 2007;13(10):1256–65. PubMed PMID: 17577246.
Bourreille A, Jarry M, D'Halluin PN, Ben-Soussan E, Maunoury V, Bulois P, et al. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn’s disease: a prospective study. Gut. 2006;55(7):978–83. PubMed PMID: 16401689, Pubmed Central PMCID: 1856304.
Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut. 2010;59(6):752–9. PubMed PMID: 20551460.
D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–86. PubMed PMID: 17258735.
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15(9):1295–301. PubMed PMID: 19340881.
Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5(5):477–83. PubMed PMID: 21939925.
Jones J, Loftus Jr EV, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6(11):1218–24. PubMed PMID: 18799360.
Flynn A, Kane S. Mucosal healing in Crohn’s disease and ulcerative colitis: what does it tell us? Curr Opin Gastroenterol. 2011;27(4):342–5. PubMed PMID: 21378560.
Viscido A, Corrao G, Taddei G, Caprilli R. “Crohn’s disease activity index” is inaccurate to detect the post-operative recurrence in Crohn’s disease. A GISC study. Gruppo Italiano per lo Studio del Colon e del Retto. Ital J Gastroenterol Hepatol. 1999;31(4):274–9. PubMed PMID: 10425569.
Regueiro M, Kip KE, Schraut W, Baidoo L, Sepulveda AR, Pesci M, et al. Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis. 2011;17(1):118–26. PubMed PMID: 20848538.
Walters TD, Steinhart AH, Bernstein CN, Tremaine W, McKenzie M, Wolff BG, et al. Validating Crohn’s disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis. 2011;17(7):1547–56. PubMed PMID: 21674711.
Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8(4):244–50. PubMed PMID: 12131607.
Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30(7):699–706. PubMed PMID: 7481535.
Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002;97(4):947–53. PubMed PMID: 12003431.
Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138(2):463–8; quiz e10-1. PubMed PMID: 19818785.
Rutgeerts P, Reinisch W, Thakkar R, Wu E, Kaltenboeck A, Yang M, et al. Long-term clinical benefits for adalimumab-treated patients with moderate to severe Crohn’s disease is predicted by early mucosal healing status. DDW; Chicago; 2011.
Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm Bowel Dis. 2009;15(3):375–82. PubMed PMID: 19009634.
Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145(1):166–75 e8. PubMed PMID: 23541909.
Thakkar K, Lucia CJ, Ferry GD, McDuffie A, Watson K, Tsou M, et al. Repeat endoscopy affects patient management in pediatric inflammatory bowel disease. Am J Gastroenterol. 2009;104(3):722–7. PubMed PMID: 19209163.
Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, et al. Risk of early surgery for Crohn’s disease: implications for early treatment strategies. Am J Gastroenterol. 2003;98(12):2712–8. PubMed PMID: 14687822.
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130(3):650–6. PubMed PMID: 16530505.
Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn’s disease: top-down or step-up? Dig Dis. 2007;25(3):260–6. PubMed PMID: 17827952.
van Lent AU, D’Haens GR. Management of postoperative recurrence of Crohn’s disease. Dig Dis. 2013;31(2):222–8. PubMed PMID: 24030230.
Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55(1):i36–58. PubMed PMID: 16481630, Pubmed Central PMCID: 1859996.
Rutgeerts P, Van Assche G. What is the role of endoscopy in the postoperative management of Crohn’s disease? Inflamm Bowel Dis. 2008;14(2):S179–80. PubMed PMID: 18816676.
Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4(1):63–101. PubMed PMID: 21122490.
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany S, Gorelik A, et al. Optimising post-operative Crohn’s disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. The POCER study Gastroenterology. 2013;144:S-164.
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Gorelik A, Liew D, et al. Clinical risk stratification predicts development of endoscopic recurrence after Crohn’s disease surgery: early results from the POCER study. Gastroenterology. 2012;142(5 Suppl 1):S-568.
Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70 e5; quiz e31. PubMed PMID: 21945953.
Lemann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128(7):1812–8. PubMed PMID: 15940616.
Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89. PubMed PMID: 20427401.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–53. PubMed PMID: 16698746, Pubmed Central PMCID: 1856208.
van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2012;7. PubMed PMID: 23135759.
Ordás I, García-Bosch O, Rodríguez S, Aceituno M, Pellise M, Ricart E, et al. Validation of a Magnetic Resonance Index of Activity for Ileocolonic Crohn’s Disease. Gastroenterology. 2010;138(5 Suppl 1):75.
Rimola J, Ordas I, Rodriguez S, Panes J. Colonic Crohn’s disease: value of magnetic resonance colonography for detection and quantification of disease activity. Abdom Imaging. 2010;35(4):422–7. PubMed PMID: 19536590.
Rimola J, Rodriguez S, Garcia-Bosch O, Ordas I, Ayala E, Aceituno M, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut. 2009;58(8):1113–20. PubMed PMID: 19136510.
Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619–35. PubMed PMID: 22842618.
Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14(1):40–6. PubMed PMID: 18022866.
Sipponen T, Karkkainen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28(10):1221–9. PubMed PMID: 18752630.
Kiesslich R, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut. 2012;61(8):1146–53. PubMed PMID: 22115910, Pubmed Central PMCID: 3388727.
Neumann H, Vieth M, Atreya R, Grauer M, Siebler J, Bernatik T, et al. Assessment of Crohn’s disease activity by confocal laser endomicroscopy. Inflamm Bowel Dis. 2012;18(12):2261–9. PubMed PMID: 22344873.
Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut. 2002;50(3):III37–42. PubMed PMID: 11953331, Pubmed Central PMCID: 1867680.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Active terminal ileal CD. (AVI 170,996 kb)
Colonic CD. (MOV 333,282 kb)
Example of Rutgeerts i1 recurrence of CD. (AVI 84,348 kb)
Example of Rutgeerts i4 recurrence of CD. (AVI 178,761 kb)
Improvement in terminal ileal CD appearance following infliximab. (AVI 189,275 kb)
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Samaan, M.A., D’Haens, G. (2015). The Use of Endoscopy to Follow the Clinical Course of Crohn’s Disease. In: Kozarek, R., Chiorean, M., Wallace, M. (eds) Endoscopy in Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-11077-6_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-11077-6_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-11076-9
Online ISBN: 978-3-319-11077-6
eBook Packages: MedicineMedicine (R0)